文献速递银屑病与炎症性皮肤病

阿达木单抗治疗甲银屑病:3期随机对照试验前26周疗效与安全性

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
PubMed 文献 · J Am Acad Dermatol · 2017-10-06

这项3期随机对照试验评估阿达木单抗治疗中重度指甲银屑病合并中重度斑块状银屑病的疗效与安全性,217例患者按1:1随机接受阿达木单抗40mg隔周1次或安慰剂。第26周主要终点NAPSI75应答率为安慰剂3.4%对比阿达木单抗46.6%(P<.001),所有排序次要终点均达标,未发现新的安全风险。

要点

  • 第26周NAPSI75应答率阿达木单抗46.6%显著高于安慰剂3.4%(P<.001)
  • 所有排序次要终点(甲NAPSI、甲痛、生活质量等)均显著改善
  • 严重不良事件率4.6%对7.3%、严重感染率1.9%对3.7%,未见新安全信号

核心结论

  • 第26周阿达木单抗治疗中重度甲银屑病在主要终点及全部排序次要终点上显著优于安慰剂,未发现新的安全风险。

研究设计与样本

  • 3期随机、安慰剂对照试验,217例中重度指甲银屑病合并中重度斑块状银屑病患者按1:1随机分配,108例安慰剂、109例阿达木单抗40mg隔周1次。
  • 188例(86.6%)完成26周A期治疗或提前转入开放标签期。

主要发现

  • 第26周NAPSI75应答率安慰剂3.4%对比阿达木单抗46.6%(P<.001),研究达到主要终点。
  • 全部排序次要终点均达到,包括全指甲NAPSI与改良NAPSI、甲痛、甲银屑病躯体功能严重度、Brigham头皮甲反向掌跖银屑病指数及医生总体评估(指甲银屑病)。
  • A期严重不良事件率安慰剂4.6%对比阿达木单抗7.3%,严重感染率1.9%对比3.7%。

关键数值与推荐

  • 主要终点为第26周NAPSI75应答率:安慰剂3.4%对比阿达木单抗46.6%,P<.001。
  • A期严重不良事件率:安慰剂4.6%对比阿达木单抗7.3%;严重感染率:1.9%对比3.7%。

临床怎么用

  • 对中重度指甲银屑病合并斑块状银屑病患者,阿达木单抗40mg隔周1次可在26周显著改善甲损害及甲痛等症状。
  • 用药期间需关注严重感染等不良事件,本试验未发现新的安全风险。

局限性

  • BSA受累低于5%的患者不符合入组条件,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous clinical trials have not evaluated improvement in nail psoriasis as a primary end point. OBJECTIVE: This phase 3 trial evaluated the safety and efficacy of adalimumab in patients with moderate-to-severe fingernail psoriasis and moderate-to-severe plaque psoriasis. METHODS: Patients were randomized 1:1 to 40 mg adalimumab every other week or placebo. The primary efficacy end point was at least 75% improvement in total-fingernail modified Nail Psoriasis Severity Index (NAPSI75) response rate at week 26. Ranked secondary end point scores evaluated at week 26 were total-fingernail NAPSI and modified NAPSI, nail pain, Nail Psoriasis Physical Functioning Severity, Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index, and Physician's Global Assessment (fingernail psoriasis). RESULTS: Of the 217 randomized patients (108 received placebo and 109 received adalimumab), 188 (86.6%) completed 26 weeks of treatment (period A) or escaped early to the open-label period. The study met the primary end point (response rate of 3.4% with placebo vs 46.6% with adalimumab [P < .001]) and all ranked secondary end points. The serious adverse event rates (placebo vs adalimumab) in period A were 4.6% versus 7.3%; the serious infections rates were 1.9% versus 3.7%. LIMITATIONS: Patients with less than 5% BSA involvement were not eligible for enrollment. CONCLUSIONS: After 26 weeks of adalimumab treatment, significant improvements were seen in the primary and all ranked secondary end points and in signs and symptoms of moderate-to-severe nail psoriasis versus with placebo and no new safety risks were identified.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Elewski BE, Okun MM, Papp K, et al. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol. 2017. PMID: 28993005. doi:10.1016/j.jaad.2017.08.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。